Head-to-head · WeighScore
LVNG RX vs NuuVim
The verdict
NuuVim takes it — 71.1/100 to 62.5/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | LVNG RX | NuuVim |
|---|---|---|
| WeighScore | 62.5/100 | 71.1/100 |
| Grade | C | C |
| Scorecard rank | #272 | #101 |
| Semaglutide | $149/mo (starting dose, compounded) | $79/mo (all doses, compounded) |
| Tirzepatide | $249/mo (microdose tier, starting dose, compounded) | $133/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #272 · C
Strengths
- One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
- States you are charged nothing if a provider does not approve you for treatment
- Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
- Semaglutide from $149/mo is competitive against the wider compounded market
- Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide
Where it loses points
- Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
- Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
- Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
- The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
- No compounding pharmacy, medical group or individual clinician is named anywhere on the site
Graded #101 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.